📰 Fred Saad News
Page 2 - Fred Saad News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fred Saad. Real-time updates on events, politics, business and more.
February 17, 2022
SAN FRANCISCO  — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study. The findings, presented at ASCO Genitourinary Cancers Symposium, showed men experienced the benefit regardless of homologous
February 15, 2022
Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate
February 15, 2022
(RTTNews) - AstraZeneca PLC (AZN.L, AZN) Tuesday announced positive results from the PROpel Phase III trial of Lynparza (olaparib) plus abirateron...
February 15, 2022
AstraZeneca and MSD's Lynparza combo delays progression risk in prostate cancer
February 15, 2022
LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) Tuesday announced positive results from the PROpel Phase III trial of Lynparza (olaparib) plus abiraterone in 1st-line metastatic castration-resistant
September 12, 2021
AUA 2021 Phase 3 HERO Study, gonadotropin-releasing hormone (GnRH) agonists and antagonists, Relugolix vs Leuprolide, safety and efficacy of relugolix in men with advanced prostate cancer.
January 20, 2021
Published 19 January 2021 Background - To investigate the effect of frailty on short-term postoperative outcomes in patients with prostate cancer treated with radical prostatectomy (RP). Methods - Within the National Inpatient Sample database, we identified 91,618 RP patients treated between 2008 and 2015. The Johns Hopkins Adjusted Clinical Groups frailty-defining indicator was applied, and we examined the rates of frailty over time, as well as its effect on overall complications, major comp...